diabetes
Lilly accused of anti-competitive practices
May 17, 2011Amylin, Boehringer, diabetes, exenatide, lilly, linagliptin
Amylin Pharmaceuticals is suing Eli Lilly and Company for alleged anticompetitive activity around Lilly’s January agreement with Boehringer Ingelheim to …
New product can overtake Lantus, says Novo leader
May 11, 2011Sales and Marketing Novo Nordisk, degludec, diabetes, insulin
Novo Nordisk’s new insulin product can eclipse Sanofi’s Lantus within just a few years of its launch, according to Novo’s …
Sanofi abandons $375m oral diabetes deal
May 9, 2011Sales and Marketing Metabolex, Sanofi, diabetes
Sanofi has terminated its $375 million deal with US biotech Metabolex to develop a novel oral anti-diabetic treatment. The French …
US approval for Boehringer’s diabetes drug Tradjenta
May 3, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Tradjenta, the once-daily oral type II diabetes treatment developed by Boehringer Ingelheim, has been approved by US regulators. The FDA …
Diabetes trial disappointment for GSK and Tolerx
March 14, 2011Research and Development DEFEND-1, DEFEND-2, GSK, GlaxoSmithKline, Tolerx, diabetes, otelixizumab, type I diabetes
GSK and Tolerx’s type I diabetes drug otelixizumab has failed to meet its primary endpoint in a late-stage trial. Anti-CD3 …
Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Onglyza expands European licence
March 4, 2011Sales and Marketing AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes
European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that …
Digital Pharma: online campaign directory updated
March 4, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra
The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …
Sanofi picks two agencies for UK diabetes account
February 25, 2011Medical Communications Lantus, Sanofi-Aventis, Tudor Reilly, diabetes, medical communications account win, red health
Healthcare PR agencies Tudor Reilly and Red Health have jointly won the Sanofi-Aventis UK diabetes account after a five-way pitch. …
Diabetes success for Sanofi, disappointment for Roche
February 2, 2011Roche, Sanofi, diabetes
The contrasting fortunes of two new diabetes became clear today, with Sanofi-Aventis lixisenatide performing well, as Roche abandoned taspoglutide.Sanofi’s lixisenatide, …
GSK settles Avandia case out of court
February 1, 2011Sales and Marketing Avandia, GSK, diabetes
GlaxoSmithKline this week settled a US federal lawsuit regarding its diabetes drug Avandia before it went to court. The company …
Digital Pharma: Sanofi launches diabetes blog
January 17, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Sanofi-Aventis, blog, diabetes
Sanofi-Aventis has ramped up its social media efforts with the launch of a blog about diabetes for US consumers. The …
Diabetes drugs show promise in Alzheimer’s
January 17, 2011Research and Development Alzheimer's, Alzheimer’s, Byetta, Novo Nordisk, Victoza, diabetes, exenatide, lilly, liraglutide
Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease. Researchers at …
Lilly and Boehringer sign major diabetes collaboration
January 12, 2011Research and Development BI10773, Boehringer Ingelheim, Eli Lilly, LY2605541, LY2963016, TGF-beta monoclonal antibody, diabetes, lilly, linagliptin, type II diabetes
Eli Lilly and Boehringer Ingelheim have signed a multi-million dollar collaboration that will see them develop and commercialise a mid- …
Novo to develop oral insulin
December 22, 2010Research and Development Emisphere, Novo Nordisk, diabetes, insulin, oral insulin, type I diabetes
Novo Nordisk is to develop an oral formulation of insulin with US biotech company Emisphere Technologies. The New Jersey-based biotech …
Latest content
